NEW YORK (GenomeWeb) – Fitch Ratings today affirmed Quest Diagnostics' ratings at BBB with a stable ratings outlook. 

The rating action applies to about $3.86 billion of debt. 

Fitch noted Quest's leading position in a fragmented and competitive US clinical laboratory market, saying its scale "affords the opportunity for comparatively efficient operations and supplies sourcing, and the ability to drive associated margin improvement following" merger and acquisition deals. 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

NPR reports that Turkish high school students will no longer study evolution.

Researchers report they sequenced and identified plant species in an "al fresco" laboratory.

An Australian team searches for genetic alterations linked to depression in hopes of developing personalized treatments, the Sydney Morning Herald reports.

In PNAS this week: host contributors to typhoid fever risk, effects of obesity-related variants near TMEM18, and more.